Zobrazeno 1 - 10
of 302
pro vyhledávání: '"Javid Moslehi"'
Autor:
Paul Gougis, Floriane Jochum, Baptiste Abbar, Elise Dumas, Kevin Bihan, Bénédicte Lebrun-Vignes, Javid Moslehi, Jean-Philippe Spano, Enora Laas, Judicael Hotton, Fabien Reyal, Anne-Sophie Hamy, Joe-Elie Salem
Publikováno v:
EClinicalMedicine, Vol 70, Iss , Pp 102536- (2024)
Summary: Background: Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment by harnessing the immune system but ICI can induce life-threatening immune-related adverse events (irAE) affecting every organ. Methods: We extracted irAE fr
Externí odkaz:
https://doaj.org/article/ae6e36526ea542228ff87171701f0137
Autor:
Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia
Publikováno v:
HemaSphere, Vol 7, p e98838e7 (2023)
Externí odkaz:
https://doaj.org/article/d5c07de1c1104e7abf60a32c2df2ca80
Autor:
Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) therapy may vary substantially in their clinical presentation, including natural history, outcomes to treatment, and patterns. The application of clinical guideli
Externí odkaz:
https://doaj.org/article/ce3651e8e8104a2ca8905bdbc8dd0dd4
Autor:
Piotr Szczepaniak, Mateusz Siedlinski, Diana Hodorowicz-Zaniewska, Ryszard Nosalski, Tomasz P. Mikolajczyk, Aneta M. Dobosz, Anna Dikalova, Sergey Dikalov, Joanna Streb, Katarzyna Gara, Pawel Basta, Jaroslaw Krolczyk, Joanna Sulicka-Grodzicka, Ewelina Jozefczuk, Anna Dziewulska, Blessy Saju, Iwona Laksa, Wei Chen, John Dormer, Maciej Tomaszewski, Pasquale Maffia, Marta Czesnikiewicz-Guzik, Filippo Crea, Agnieszka Dobrzyn, Javid Moslehi, Tomasz Grodzicki, David G. Harrison, Tomasz J. Guzik
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 13 (2022)
Cardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and
Externí odkaz:
https://doaj.org/article/4b3b8954d7104657a53492a95dc463f4
Autor:
Michelle Rosenzwajg, Joe-Elie Salem, Yves Allenbach, Stephane Ederhy, Noël Zahr, Jean-Paul Mira, Lee S Nguyen, Javid Moslehi, Marie Bretagne, Jennifer Arrondeau, Baptiste Abbar, Bruno Pinna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/b52d42ec7efd48709f7ba5fce570309a
Autor:
Joshua A. Beckman, MD, Sean P. Doherty, BA, Zachary B. Feldman, BA, Emily S. Banks, BS, Javid Moslehi, MD, Iris Z. Jaffe, MD, PhD, Naomi M. Hamburg, MD, Quanhu Sheng, PhD, Jonathan D. Brown, MD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 5, Pp 567-574 (2019)
Summary: In this study low-input RNA-sequencing was used to annotate the molecular identity of endothelial cells isolated and immunopurified with CD144 microbeads. Using this technique, comparative gene expression profiling from healthy subjects and
Externí odkaz:
https://doaj.org/article/b728fbf090354e778a680e203eefa2d7
Autor:
Muthiah Vaduganathan, MD, MPH, Sameer A. Hirji, MD, MPH, Arman Qamar, MD, Navkaranbir Bajaj, MD, MPH, Ankur Gupta, MD, PhD, Vlad G. Zaha, MD, Alvin Chandra, MD, Mark Haykowsky, PhD, Bonnie Ky, MD, MSCE, Javid Moslehi, MD, Anju Nohria, MD, Javed Butler, MD, MPH, MBA, Ambarish Pandey, MD, MSCS
Publikováno v:
JACC. CardioOncology, Vol 1, Iss 1, Pp 54-65 (2019)
Objectives: This study sought to assess the effects of neurohormonal therapies in preventing cardiotoxicity in patients receiving chemotherapy. Background: Various cardioprotective approaches have been evaluated to prevent chemotherapy-related cardio
Externí odkaz:
https://doaj.org/article/40f9d47a2efc4997b25c909e78ba9746
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/2a8484dd1a7a46bebd72634103f52bce
Autor:
James Allison, Spencer Wei, Douglas Johnson, Elizabeth Wescott, Justin Balko, Margaret Axelrod, Wouter Meijers, Elie Tannous, Xiaopeng Sun, Juan Qin, Ayaka Sugiura, Elles Screever, Susan Opalenik, Yueli Zhang, Javid Moslehi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/e0622f78fa764167a6db867967ab1ab0
Autor:
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://doaj.org/article/539d278310f84aa3955bb4b7eb5f3b1d